Highly Drug-resistant Focal Epilepsy
Conditions
Keywords
Drug-resistance, focal epilepsy, partial-onset seizures
Brief summary
The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy. Also, the effects of UCB0942 on the patient's quality of life will be explored.
Detailed description
For those subjects who benefit substantially from UCB0942 in the multicenter, randomized, double-blind, placebo-controlled, parallel group study EP0069, the current open-label extension study EP0073 will provide an opportunity to continue UCB0942 treatment after a careful evaluation of the individual benefit-risk balance and with close monitoring of safety, tolerability and efficacy of long-term study treatment.
Interventions
DRUGUCB0942
* Active Substance: UCB0942 * Pharmaceutical form: Film-coated tablet * Concentration: 25 mg, 100 mg or 200 mg * Route of Administration: oral
Sponsors
UCB Biopharma SRL
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A written Informed Consent form approved by the Independent Ethics Committee is signed and dated by the subject, after the Investigator assesses whether the subject is able to understand the potential risks and benefits of participating in the study * Subject must have completed Visit 13 (V13) of the Outpatient Maintenance Period of EP0069 to be eligible for enrollment into EP0073 * In EP0069, the subject demonstrated a reduction in frequency and/or severity of seizures as compared to baseline that is considered clinically significant by the Investigator and significant by the subject * In EP0069, the subject experiences substantial benefit from UCB0942 with acceptable tolerability according to the subject and Investigator * No tolerability issues that can outweigh attained benefits, in the opinion of the Investigator * Female subjects of nonchildbearing potential (premenarcheal, postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, and complete hysterectomy) are eligible. Female subjects of childbearing potential are eligible if they use medically accepted contraceptive methods * Male subject confirms that, during the study period and for a period of 3 months after the final dose, when having sexual intercourse with a woman of childbearing potential, he will use a barrier contraceptive (eg, condom)
Exclusion criteria
* Subject has active suicidal ideation as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the 'Since Last Visit' version of the Columbia Suicide Severity Rating Scale. The subject should be referred immediately to a Mental Healthcare Professional and must be withdrawn from the study * Subject has taken other (non-Anti-Epileptic Drug) prescription, non-prescription, dietary (eg, grapefruit or passion fruit), or herbal products that are potent inducers or inhibitors of the CYP3A4 pathway for 2 weeks (or 5 half lives whichever is longer) prior to study entry * Subject has an abnormality in the 12-lead electrocardiography that, in the opinion of the Investigator, increases the risks associated with participating in the study. In addition, any subject with any of the following findings will be excluded: 1. Prolonged QTc (Bazett's, machine-read) interval defined as \> 450 ms for males and \> 470 ms for females 2. Bundle branch blocks and other conduction abnormalities other than mild first degree atrioventricular block (defined as PR interval \>= 220 ms) 3. Irregular rhythms other than sinus arrhythmia or occasional, rare supraventricular or rare ventricular ectopic beats 4. In the judgment of the Investigator, T-wave configurations are not of sufficient quality for assessing QT interval duration * Subject has a clinically significant abnormality on echocardiography at the Entry Visit (V2) of EP0073 * Upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \>ULN total bilirubin (\>=1.5xULN total bilirubin if known Gilbert's syndrome) at the EV (V2) of EP0073 (V15 of EP0069). If subject has elevations only in total bilirubin that are \>ULN and \<1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin \<35%). For enrolled subjects with a baseline result * ULN for ALT, AST, ALP, or total bilirubin, a baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the electronic Case Report form (eCRF). If subject has \>ULN ALT, AST, or ALP that does not meet the exclusion limit at screening (ie, the value is * ULN but \<=2xULN at the EV \[V2\] of EP0073), repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject must be discussed with the Medical Monitor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 75% Responder Rate by 3-month Interval (Month >54-57) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >54-57) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >33-36) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >33-36) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >36-39) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >36-39) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >39-42) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >39-42) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >42-45) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >42-45) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >45-48) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >45-48) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >48-51) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >48-51) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >51-54) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >51-54) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) From the Beginning at Entry Visit (EV) of the Evaluation Period to End of Safety Follow-Up Visit During the EP0073 Study | From Entry Visit to End of Safety Follow-Up Visit (up to 5 years) | An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Percentage of participants experiencing at least one treatment-emergent adverse event (reported by the participant and/or caregiver or observed by the Investigator or inpatient staff) are reported. |
| 75% Responder Rate by 3-month Interval (Month 0 to 3) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month 0-3) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >3-6) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >3-6) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >6-9) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >6-9) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >9-12) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >9-12) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >12-15) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >12-15) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >15-18) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >15-18) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >18-21) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >18-21) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >21-24) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >21-24) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >24-27) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >24-27) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >27-30) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >27-30) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
| 75% Responder Rate by 3-month Interval (Month >30-33) Over the Evaluation Period | Over 3-month interval over the Evaluation Period (Month >30-33) | A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period | Median partial-onset seizure frequency per 28 days by seizure type (Type IA1, Type IB, Type IC) by 3-month intervals over the Evaluation Period of the EP0073 study was reported. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. |
| Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period, Relative to Baseline (of EP0069) | Percent change from Baseline in seizure frequency for observable focal-onset seizures (Type IA1, IB, and IC) to the corresponding interval was calculated using the following formula: change from Baseline in the 28 day adjusted seizure frequency/28 day adjusted seizure frequency during the EP0069 2- week Prospective Outpatient Baseline Period × 100. The numerator is calculated by subtracting the 28-day adjusted seizure frequency during the Period of interest from the 28-day adjusted seizure frequency during the EP0069 2-week prospective outpatient Baseline Period. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. |
| 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period | A 50% responder was defined as a participant with a ≥50% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 50% responders during the period/number of participants during the period × 100. |
| Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period | The number of seizure-free days is defined as the total number of days within an analysis Period or time interval for which no seizures were reported. The percentage of seizure-free days is to be computed as 100 times the number of seizure-free days divided by the number of days for which daily diary data was available in the specified analysis Period. Days without the corresponding daily diary data (ie, Not Done is ticked) are not used in these computations. |
| Seizure-free Rate Over the Evaluation Period | Over the Evaluation Period (up to 5 years) | Participants were considered seizure free for a given Period or time interval if the participant, completes the Period or time interval, reports no seizures during the Period, and has no more than 10% of days in the Period for which seizure data is not available (ie, Not Done is reported on the Seizure Count CRF). The seizure freedom rate (%) for a specific time Period was calculated using the following formula: Count of seizure free participants during the Period/ Number of participants during the Period × 100. |
| Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | Month 3, 7, 13, 19, 25, 31, 37, 43, 49, early discontinuation visit (EDV) (up to Month 58), Relative to Baseline (of EP0069) | The QOLIE-31-P includes 30 items grouped into 7 multi-item subscales (seizure worry, overall quality of life, emotional well-being, energy/fatigue, cognitive functioning, medication effects, and social function) and a health status item. Individual responses for the 30 subscale items are rescaled to 0 to 100 with higher scores reflecting better functioning. Each subscale score is then calculated by summing rescaled responses for that subscale and dividing by number of items with non-missing response. Responses for health status item are multiple of 10 ranging from 0 to 100 with a higher score corresponding to better health status. The QOLIE-31-P total score was calculated as weighted sum of the subscale scores which ranges from 0 to 100 with higher score reflecting better functioning. |
| Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period | Median partial-onset seizure frequency per 28 days by 3-month intervals over the Evaluation Period of the EP0073 study was reported. |
Countries
Belgium, Bulgaria, Germany, Hungary, Netherlands, Spain
Participant flow
Recruitment details
The study started to enroll study participants in December 2015 and concluded in November 2020.
Pre-assignment details
Participant flow refers to the Safety Set. Participants who experienced substantial benefit from UCB0942 with acceptable tolerability in the EP0069 (NCT02495844) study had opportunity to continue treatment in this study.
Participants by arm
| Arm | Count |
|---|---|
| UCB0942 All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg twice daily \[bid\]), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. | 42 |
| Total | 42 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 3 |
| Overall Study | For the Promoter | 1 |
| Overall Study | Lack of Efficacy | 16 |
| Overall Study | Negative Benefit/Risk | 1 |
| Overall Study | Participant wants to be pregnant | 2 |
| Overall Study | Protocol Deviation | 2 |
| Overall Study | Somnolence | 1 |
| Overall Study | Sponsor's Decision | 9 |
| Overall Study | Study terminated by Sponsor | 7 |
Baseline characteristics
| Characteristic | UCB0942 |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 42 Participants |
| Age, Continuous | 35.4 years STANDARD_DEVIATION 10.5 |
| Race/Ethnicity, Customized Other/mixed | 2 Participants |
| Race/Ethnicity, Customized White | 40 Participants |
| Sex: Female, Male Female | 21 Participants |
| Sex: Female, Male Male | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 42 |
| other Total, other adverse events | 32 / 42 |
| serious Total, serious adverse events | 12 / 42 |
Outcome results
Primary
75% Responder Rate by 3-month Interval (Month 0 to 3) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month 0-3)
Population: The Full Analysis Set (FAS) consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month 0 to 3) Over the Evaluation Period | 24.4 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >12-15) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >12-15)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >12-15) Over the Evaluation Period | 23.1 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >15-18) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >15-18)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >15-18) Over the Evaluation Period | 23.1 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >18-21) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >18-21)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >18-21) Over the Evaluation Period | 26.9 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >21-24) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >21-24)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >21-24) Over the Evaluation Period | 27.3 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >24-27) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >24-27)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >24-27) Over the Evaluation Period | 26.1 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >27-30) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >27-30)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >27-30) Over the Evaluation Period | 33.3 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >30-33) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >30-33)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >30-33) Over the Evaluation Period | 25.0 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >33-36) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >33-36)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >33-36) Over the Evaluation Period | 35.0 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >36-39) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >36-39)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >36-39) Over the Evaluation Period | 27.8 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >3-6) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >3-6)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >3-6) Over the Evaluation Period | 24.4 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >39-42) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >39-42)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >39-42) Over the Evaluation Period | 27.8 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >42-45) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >42-45)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >42-45) Over the Evaluation Period | 50.0 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >45-48) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >45-48)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >45-48) Over the Evaluation Period | 40.0 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >48-51) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >48-51)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >48-51) Over the Evaluation Period | 40.0 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >51-54) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >51-54)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >51-54) Over the Evaluation Period | 40.0 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >54-57) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >54-57)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >54-57) Over the Evaluation Period | 0 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >6-9) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >6-9)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >6-9) Over the Evaluation Period | 20.6 percentage of participants |
Primary
75% Responder Rate by 3-month Interval (Month >9-12) Over the Evaluation Period
A 75% responder is defined as a participant with a ≥75% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period × 100.
Time frame: Over 3-month interval over the Evaluation Period (Month >9-12)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | 75% Responder Rate by 3-month Interval (Month >9-12) Over the Evaluation Period | 28.6 percentage of participants |
Primary
Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) From the Beginning at Entry Visit (EV) of the Evaluation Period to End of Safety Follow-Up Visit During the EP0073 Study
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Percentage of participants experiencing at least one treatment-emergent adverse event (reported by the participant and/or caregiver or observed by the Investigator or inpatient staff) are reported.
Time frame: From Entry Visit to End of Safety Follow-Up Visit (up to 5 years)
Population: The Safety Set (SS) consisted of all enrolled study participants who took at least 1 dose of UCB0942 in the EP0073 study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) From the Beginning at Entry Visit (EV) of the Evaluation Period to End of Safety Follow-Up Visit During the EP0073 Study | 90.5 percentage of participants |
Secondary
50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study
A 50% responder was defined as a participant with a ≥50% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 50% responders during the period/number of participants during the period × 100.
Time frame: Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment and number analyzed signifies participants who were evaluable at specified time points.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month 0-3 | 51.2 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >33-36 | 65.0 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >39-42 | 72.2 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >3-6 | 39.0 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >6-9 | 58.8 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >9-12 | 67.9 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >12-15 | 65.4 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >15-18 | 53.8 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >18-21 | 57.7 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >21-24 | 72.7 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >24-27 | 69.6 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >27-30 | 66.7 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >30-33 | 70.0 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >36-39 | 72.2 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >42-45 | 64.3 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >45-48 | 80.0 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >48-51 | 90.0 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >51-54 | 80.0 percentage of participants |
| UCB0942 (SS) | 50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >54-57 | 100 percentage of participants |
Secondary
Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073
The QOLIE-31-P includes 30 items grouped into 7 multi-item subscales (seizure worry, overall quality of life, emotional well-being, energy/fatigue, cognitive functioning, medication effects, and social function) and a health status item. Individual responses for the 30 subscale items are rescaled to 0 to 100 with higher scores reflecting better functioning. Each subscale score is then calculated by summing rescaled responses for that subscale and dividing by number of items with non-missing response. Responses for health status item are multiple of 10 ranging from 0 to 100 with a higher score corresponding to better health status. The QOLIE-31-P total score was calculated as weighted sum of the subscale scores which ranges from 0 to 100 with higher score reflecting better functioning.
Time frame: Month 3, 7, 13, 19, 25, 31, 37, 43, 49, early discontinuation visit (EDV) (up to Month 58), Relative to Baseline (of EP0069)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment and number analyzed signifies participants who were evaluable at specified time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| UCB0942 (SS) | Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | Month 3 | 3.1 scores on a scale | Standard Deviation 14.2 |
| UCB0942 (SS) | Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | Month 7 | 3.8 scores on a scale | Standard Deviation 17 |
| UCB0942 (SS) | Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | Month 13 | 6.8 scores on a scale | Standard Deviation 17.7 |
| UCB0942 (SS) | Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | Month 19 | 5.7 scores on a scale | Standard Deviation 18 |
| UCB0942 (SS) | Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | Month 25 | 4.7 scores on a scale | Standard Deviation 24.8 |
| UCB0942 (SS) | Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | Month 31 | 5.4 scores on a scale | Standard Deviation 21.7 |
| UCB0942 (SS) | Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | Month 37 | 3.4 scores on a scale | Standard Deviation 18.8 |
| UCB0942 (SS) | Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | Month 43 | 1.0 scores on a scale | Standard Deviation 19 |
| UCB0942 (SS) | Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | Month 49 | -4.6 scores on a scale | Standard Deviation 22.2 |
| UCB0942 (SS) | Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073 | EDV (up to Month 58) | 2.2 scores on a scale | Standard Deviation 19.9 |
Secondary
Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study
Median partial-onset seizure frequency per 28 days by 3-month intervals over the Evaluation Period of the EP0073 study was reported.
Time frame: Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number analyzed signifies participants who were evaluable at specified time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >54-57 | 7.84 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month 0-3 | 18.98 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >3-6 | 22.99 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >6-9 | 23.33 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >9-12 | 18.67 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >12-15 | 23.23 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >15-18 | 19.91 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >18-21 | 16.80 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >21-24 | 14.31 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >24-27 | 14.31 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >27-30 | 14.16 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >30-33 | 16.80 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >33-36 | 19.29 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >36-39 | 13.69 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >39-42 | 9.96 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >42-45 | 13.07 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >45-48 | 10.58 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >48-51 | 9.02 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >51-54 | 7.80 seizure frequency per 28 days |
Secondary
Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study
Median partial-onset seizure frequency per 28 days by seizure type (Type IA1, Type IB, Type IC) by 3-month intervals over the Evaluation Period of the EP0073 study was reported. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981.
Time frame: Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number analyzed signifies participants who were evaluable at specified time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >30-33 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month 0-3 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >3-6 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >6-9 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >9-12 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >12-15 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >15-18 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >18-21 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >21-24 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >24-27 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >27-30 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >30-33 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >33-36 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >36-39 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >39-42 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >42-45 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >45-48 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >48-51 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >51-54 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IA1: Month >54-57 | 4.48 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month 0-3 | 10.73 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >3-6 | 12.67 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >6-9 | 9.33 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >9-12 | 9.64 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >12-15 | 15.56 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >15-18 | 13.38 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >18-21 | 13.07 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >21-24 | 7.78 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >24-27 | 9.80 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >27-30 | 9.49 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >30-33 | 9.64 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >33-36 | 7.47 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >36-39 | 6.53 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >39-42 | 6.84 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >42-45 | 5.29 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >45-48 | 4.36 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >48-51 | 4.67 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >51-54 | 3.29 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IB: Month >54-57 | 3.36 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month 0-3 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >3-6 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >6-9 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >9-12 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >12-15 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >15-18 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >18-21 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >21-24 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >24-27 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >27-30 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >33-36 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >36-39 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >39-42 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >42-45 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >45-48 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >48-51 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >51-54 | 0.00 seizure frequency per 28 days |
| UCB0942 (SS) | Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Type IC: Month >54-57 | 0.00 seizure frequency per 28 days |
Secondary
Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period
The number of seizure-free days is defined as the total number of days within an analysis Period or time interval for which no seizures were reported. The percentage of seizure-free days is to be computed as 100 times the number of seizure-free days divided by the number of days for which daily diary data was available in the specified analysis Period. Days without the corresponding daily diary data (ie, Not Done is ticked) are not used in these computations.
Time frame: Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number analyzed signifies participants who were evaluable at specified time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >6-9 | 54.44 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >9-12 | 55.56 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >54-57 | 72.00 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month 0-3 | 48.33 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >3-6 | 42.81 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >12-15 | 54.44 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >15-18 | 51.11 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >18-21 | 61.11 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >21-24 | 57.78 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >24-27 | 60.00 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >27-30 | 64.44 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >30-33 | 57.78 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >33-36 | 60.00 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >36-39 | 68.89 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >39-42 | 67.78 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >42-45 | 67.78 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >45-48 | 72.22 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >48-51 | 73.33 percentage of days |
| UCB0942 (SS) | Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period | Month >51-54 | 80.65 percentage of days |
Secondary
Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study
Percent change from Baseline in seizure frequency for observable focal-onset seizures (Type IA1, IB, and IC) to the corresponding interval was calculated using the following formula: change from Baseline in the 28 day adjusted seizure frequency/28 day adjusted seizure frequency during the EP0069 2- week Prospective Outpatient Baseline Period × 100. The numerator is calculated by subtracting the 28-day adjusted seizure frequency during the Period of interest from the 28-day adjusted seizure frequency during the EP0069 2-week prospective outpatient Baseline Period. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981.
Time frame: Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period, Relative to Baseline (of EP0069)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment and number analyzed signifies participants who were evaluable at specified time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >42-45 | 68.79 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month 0-3 | 50.51 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >3-6 | 39.14 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >6-9 | 56.98 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >9-12 | 62.22 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >12-15 | 55.74 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >15-18 | 54.04 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >18-21 | 57.27 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >21-24 | 68.57 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >24-27 | 60.15 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >27-30 | 59.82 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >30-33 | 59.57 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >33-36 | 59.73 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >36-39 | 64.50 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >39-42 | 59.01 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >45-48 | 68.17 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >48-51 | 67.12 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >51-54 | 73.08 percent change |
| UCB0942 (SS) | Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study | Month >54-57 | 73.56 percent change |
Secondary
Seizure-free Rate Over the Evaluation Period
Participants were considered seizure free for a given Period or time interval if the participant, completes the Period or time interval, reports no seizures during the Period, and has no more than 10% of days in the Period for which seizure data is not available (ie, Not Done is reported on the Seizure Count CRF). The seizure freedom rate (%) for a specific time Period was calculated using the following formula: Count of seizure free participants during the Period/ Number of participants during the Period × 100.
Time frame: Over the Evaluation Period (up to 5 years)
Population: The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| UCB0942 (SS) | Seizure-free Rate Over the Evaluation Period | 0 percentage of participants |